spoke about his presentation on using bispecific antibodies for the management of multiple myeloma.

This is a rapidly growing field.

These drugs have revolutionized the treatment of multiple myeloma.

It's not even a subtle way to say it, really transformed the treatment.

And so now the question is just, how do we best use these drugs? I mean, everyone needs to be on them.

So how do we best use them? How do we sequence them? How do we make sure that every patient has access to them? And then how do we figure out just the optimal management of each of them? So the inspiration is there.

We just need to increase access for everybody because we have a gluttony of riches and we have multiple targets available and there are more coming.

and do happen unless you primary prophylax them.